A meta-analysis of randomized controlled trials has concluded that anti-PD-1/PD-L1 inhibitors are more advantageous for treating advanced and metastatic cancers than conventional therapies, with better overall survival and progression-free survival particularly in male patients with younger age, without central nervous system or liver metastasis, no EGFR mutations, and with higher PD-L1 expression (18). The gene discussed is CD274; the disease is metastasis.